2,434 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Acquired by Hager Investment Management Services LLC

Hager Investment Management Services LLC acquired a new stake in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,434 shares of the company’s stock, valued at approximately $891,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ONC. GAMMA Investing LLC raised its position in shares of BeOne Medicines by 39.5% during the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after purchasing an additional 34 shares during the period. Mather Group LLC. grew its position in BeOne Medicines by 192.0% in the 3rd quarter. Mather Group LLC. now owns 73 shares of the company’s stock valued at $27,000 after purchasing an additional 48 shares during the period. Signaturefd LLC grew its position in BeOne Medicines by 13.4% in the 3rd quarter. Signaturefd LLC now owns 414 shares of the company’s stock valued at $152,000 after purchasing an additional 49 shares during the period. Steadtrust LLC increased its stake in BeOne Medicines by 3.7% during the 2nd quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after purchasing an additional 50 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its stake in BeOne Medicines by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after purchasing an additional 52 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

Analyst Ratings Changes

ONC has been the topic of several research reports. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 18th. Guggenheim lifted their price objective on shares of BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating and set a $425.00 target price on shares of BeOne Medicines in a research report on Friday, October 16th. Nomura upped their target price on shares of BeOne Medicines from $454.75 to $484.91 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Citizens Jmp raised their price target on shares of BeOne Medicines from $405.00 to $463.00 and gave the company a “market outperform” rating in a research report on Friday. Sixteen research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $434.79.

Insider Transactions at BeOne Medicines

In other news, CEO John Oyler sold 70,907 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $361.90, for a total value of $25,661,243.30. Following the completion of the transaction, the chief executive officer directly owned 54,892 shares of the company’s stock, valued at $19,865,414.80. This represents a 56.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Chan Lee sold 2,666 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $360.00, for a total value of $959,760.00. Following the sale, the senior vice president directly owned 812 shares of the company’s stock, valued at $292,320. The trade was a 76.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 261,362 shares of company stock worth $93,689,167. 6.19% of the stock is owned by insiders.

BeOne Medicines Price Performance

BeOne Medicines stock opened at $406.96 on Monday. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $410.71. The stock has a market cap of $44.68 billion, a PE ratio of 51.71 and a beta of 0.63. The firm’s 50-day simple moving average is $363.49 and its 200 day simple moving average is $326.34. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 3.55.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Thursday, November 5th. The company reported $3.64 EPS for the quarter, beating the consensus estimate of $2.34 by $1.30. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. Research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 EPS for the current fiscal year.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported Q3 EPS of $3.64, above the $2.34 consensus, and revenue of $1.89 billion, topping estimates of $1.76 billion. The company also raised its 2026 revenue guidance, supporting a stronger outlook. Q3 earnings and guidance
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. A faster review could bring a potential label expansion sooner, though approval is not guaranteed. FDA priority review
• Positive Sentiment: Several firms raised price targets while maintaining bullish ratings: RBC to $465, Citizens JMP to $463, Truist to $448, Barclays to $446, and Wells Fargo to $435. The revisions signal continued analyst confidence in BeOne’s prospects. RBC rating information Citizens JMP rating information Truist rating information Barclays rating information Wells Fargo rating information

About BeOne Medicines

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia.

Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.